# Lncyt

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lncyt

- Industry: Pharmaceuticals
- Headquarters: Yantai, China
- Website: www.dc-lnc.com
- Latest round: Series C (Jul 17, 2025)
- Investors on record: 3

## About

Established in 2021 and based in Yantai, China, Lncyt is a drug discovery company that focuses on developing innovative nuclear drugs for diagnostic and therapeutic integration. The company has partnerships with the National University of Singapore (NUS), Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Tumor Hospital, and Beijing Tumor Hospital. It has a 6,500-square-meter integrated laboratory for targeted drug synthesis, radiolabeling, preclinical cell and animal experiments, and molecular imaging. In February 2025, it raised CNY 150.16 million in venture funding from new investors Real Power Capital, Yantai Dongcheng Pharmaceutical Group Co., Ltd, and an individual investor. In July 2025, Lncyt raised a series C+ from new investors China Cinda Asset Management, Shandong New Kinetic Energy Fund, Yantai Dongcheng Pharmaceutical Group Co., Ltd. The company’s main business is the development of innovative nuclear medicines, focusing on Class 1 integrated diagnostic and therapeutic radiopharmaceuticals. Its products are used in the field of oncology, covering a spectrum of cancer types, including prostate cancer, solid tumors, gliomas, and neuroendocrine tumors. The company generates revenue by providing targeted nuclear medicine solutions and integrated diagnostic and therapeutic services.

## Funding rounds

- Series C, Jul 17, 2025 — China Cinda Asset Management, Yantai Dongcheng Pharmaceutical Group Co., Ltd, Shandong New Growth Drivers Fund Management

## Investors

- China Cinda Asset Management — Series C
- Yantai Dongcheng Pharmaceutical Group Co., Ltd — Series C
- Shandong New Growth Drivers Fund Management (https://capitalatlas.ai/funds/shandong-new-growth-drivers-fund-management) — Series C